ABSTRACT
<p><b>OBJECTIVE</b>To investigate the effect of neoadjuvant chemotherapy on estrogen receptor (ER) and progesterone receptor (PR) expression in breast carcinoma.</p><p><b>METHODS</b>Samples were obtained from 31 patients with breast carcinoma who received neo-adjuvant chemotherapy, ER or PR expressions were analyzed in preoperative core biopsies and final surgical specimens.</p><p><b>RESULTS</b>ER level was up-regulated in 13 (41.9%) out of 31 cases, PR level was up-regulated in 10 (32.3%). Both ER level and PR level were up-regulated in 8 (25.8%) out of 31 cases.</p><p><b>CONCLUSIONS</b>Neoadjuvant chemotherapy may impact the hormone receptor status, ER and PR expression re-analysis in final surgical specimens is recommended.</p>
Subject(s)
Female , Humans , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Breast Neoplasms , Drug Therapy , Metabolism , Chemotherapy, Adjuvant , Epirubicin , Follow-Up Studies , Immunohistochemistry , Neoadjuvant Therapy , Paclitaxel , Receptors, Estrogen , Receptors, ProgesteroneABSTRACT
<p><b>OBJECTIVE</b>To investigate the estrogen receptors (ER)alpha and ERbeta expression and their relationship with clinicopathological parameters in human breast carcinoma.</p><p><b>METHODS</b>Samples were obtained from 30 breast carcinoma, reverse transcriptase polymerase chain reaction was used to measure the expression of ERalpha and ERbeta mRNA.</p><p><b>RESULTS</b>ERalpha mRNA level was up-regulated in breast carcinoma tissue compared with adjacent normal tissue (t = 7.399, P < 0.01) while down-regulated in ERbeta. The relative ratio of ERalpha and ERbeta was decreased in normal tissue vs. carcinoma (t = 6.385, P < 0.01), in patients with lymph node metastasis vs. those without lymph node metastasis (t = 2.602, P < 0.05), in late stage carcinoma vs. early stage (t = 3.754, P < 0.05).</p><p><b>CONCLUSION</b>ERalpha and ERbeta play divergent role in the development of human breast carcinoma.</p>